Asana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
July 2026 — Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Asana Spital Menziken is a regional healthcare provider based in the canton of Aargau, Switzerland, serving patients from the surrounding Wynental and Suhrental regions. The hospital provides a broad range of inpatient and outpatient medical services, including emergency care, internal medicine, surgery, radiology, physiotherapy and rehabilitation. It combines acute hospital care with long-term nursing services and works closely with general practitioners and other healthcare providers in the region.
LUKS is one of Switzerland’s leading hospital groups and provides a broad range of primary, specialized and highly specialized medical services. The group operates hospitals in Lucerne, Sursee and Wolhusen and also includes Spital Nidwalden in Stans. As a teaching and research hospital, LUKS combines regional healthcare delivery with advanced medical treatment, research and professional education.
Our role in the transaction
Oaklins’ team in Switzerland acted as the exclusive M&A advisor to Asana Spital Menziken and its owner in this transaction.
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreSynergia and Bolster have secured acquisition financing for Life & Mobility
Synergia Capital Partners and Bolster Investment Partners have partnered with Life & Mobility, a leading Dutch developer and manufacturer of premium mobility and rehabilitation solutions. The partnership marks an important next step in Life & Mobility’s growth trajectory, focused on further international expansion, continued product innovation and strengthening its leading market position.
Learn more